CVE-2022-29532

Public Exploit

Description

An issue was discovered in MISP before 2.4.158. There is XSS in the cerebrate view if one administrator puts a javascript: URL in the URL field, and another administrator clicks on it.

Category

4.8
CVSS
Severity: Medium
CVSS 3.1 •
CVSS 2.0 •
EPSS 0.29%
Third-Party Advisory github.com Third-Party Advisory github.com Third-Party Advisory zigrin.com Third-Party Advisory zigrin.com
Affected: n/a n/a
Published at:
Updated at:

References

Link Tags
https://github.com/MISP/MISP/compare/v2.4.157...v2.4.158 third party advisory release notes
https://github.com/MISP/MISP/commit/60c85b80e3ab05c3ef015bca5630e95eddbb1436 third party advisory patch
https://zigrin.com/cakephp-application-cybersecurity-research-protect-your-website-from-stored-xss-attacks-understanding-and-preventing-vulnerabilities-in-open-source-applications/ third party advisory exploit
https://zigrin.com/advisories/misp-xss-in-the-cerebrate-view/ third party advisory

Frequently Asked Questions

What is the severity of CVE-2022-29532?
CVE-2022-29532 has been scored as a medium severity vulnerability.
How to fix CVE-2022-29532?
To fix CVE-2022-29532, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-29532 being actively exploited in the wild?
It is possible that CVE-2022-29532 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.